Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
159 GBX | +0.95% | +0.32% | -12.88% |
May. 21 | Transcript : Arecor Therapeutics plc - Special Call | |
May. 20 | Arecor Therapeutics plc Announces Its Ultra-Concentrated, Ultra-Rapid Acting Insulins | CI |
Sales 2023 | 4.57M 5.83M | Sales 2024 * | 7.49M 9.54M | Capitalization | 48.7M 62.04M |
---|---|---|---|---|---|
Net income 2023 | -8M -10.19M | Net income 2024 * | -5M -6.37M | EV / Sales 2023 | 12.2 x |
Net cash position 2023 * | 6.16M 7.85M | Net cash position 2024 * | 1.46M 1.86M | EV / Sales 2024 * | 6.31 x |
P/E ratio 2023 |
-6.52
x | P/E ratio 2024 * |
-9.09
x | Employees | 51 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 48.52% |
Latest transcript on Arecor Therapeutics plc
1 day | +0.95% | ||
1 week | +0.32% | ||
1 month | +16.48% | ||
3 months | +15.64% | ||
6 months | -15.20% | ||
Current year | -12.88% |
Managers | Title | Age | Since |
---|---|---|---|
Sarah Howell
CEO | Chief Executive Officer | 49 | - |
Susan Lowther
DFI | Director of Finance/CFO | 65 | 18-12-31 |
Jan Jezek
CTO | Chief Tech/Sci/R&D Officer | - | 07-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Smith
BRD | Director/Board Member | 78 | - |
Christine Soden
BRD | Director/Board Member | 66 | 21-04-30 |
Andrew Richards
CHM | Chairman | 64 | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 159 | +0.95% | 30,000 |
24-05-30 | 157.5 | -0.63% | 50,876 |
24-05-29 | 158.5 | -0.94% | 21,087 |
24-05-28 | 160 | +0.95% | 22,385 |
24-05-24 | 158.5 | -.--% | 38,871 |
Delayed Quote London S.E., May 31, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-12.88% | 61.96M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- AREC Stock